Dissolvable Films: Dissolvable Films for Flexible Product Format in Drug Delivery - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Dissolvable Films: Dissolvable Films for Flexible Product Format in Drug Delivery
For pediatric and geriatric patients, fast-dissolving drug-delivery systems provide an easier way to take medications and vitamins. Oral thin films have evolved to provide systemic delivery of active pharmaceutical ingredients for over-the-counter and soon, prescription drugs. The authors review the practical benefits of dissolvable films, their manufacture, and their market potential.


Pharmaceutical Technology


Addressing solid-dose manufacturing trends

Several emerging trends in solid-dose manufacturing may be more easily overcome by OTF formats than other solid forms. A push toward developing low-dose, high-potency formulations (6) is leading to improvements in drug formulation. These include the conversion of drug substances to new forms such as from salt- to free-base, modified crystal morphology, and nanoparticles, which may present challenges for traditional solid-dose manufacturing. For example, nanoparticle drug substances may segregate more easily than micronized counterparts during the powder-blending and powder-flow processes that lead into the direct-compression operations in solid-dose manufacturing. Because APIs typically are added into bulk fluids in various ways before casting OTFs (suspensions, emulsions, or solutions), new high-potency drug forms do not present any unique barriers to OTF formulation and manufacturing.

A second trend is the increasing need for dosage formats using poorly soluble drugs (6). One solution to improving poorly soluble API delivery is through particle-size reduction such as nanoparticles. Other mechanisms include preparing the drug substance as a microemulsion or using co-solvents to solubilize the API. OTF formats can accommodate any of these techniques during manufacturing.

Flexibility in formulation

An inherent benefit of the OTF format to drug manufacturers is the flexibility of film formulation for a wide range of eligible APIs. A number of physical properties can be altered, including film-dissolution rates, material composition, and API absorption rates (5).


Figure 1
Customizing dissolution rates. OTFs are produced by combining water-soluble components and additives to attain a desired dissolution rate when exposed to a fluid. By modifying the combination of film-forming polymers and film thickness, formulators can design films to release their APIs in seconds, or for controlled-release applications, to deliver the dose over a period of hours (see Figure 1).

Formulators may select materials from several water-soluble polymers to deliver the desired film strength and disintegration properties. Examples of water-soluble polymers include natural gums, polyethelene oxide, derivatives of cellulose, polyvinyl pyrrolidone, polyvinyl alcohol, and acrylic-based polymers (7). The optimal properties of film strength and disintegration are obtained with the selection of a particular combination of hydrophilic polymers.

Material sets are tailored to meet specific guidances and regulations. Scientists have various formulary options to address regulatory and compliance needs including, but not limited to:

  • Bovine spongiform encephalopathy/transmissible spongiform encephalopathies (BSE/TSE)
  • Nongenetically modified organisms (non-GMO)
  • United States Pharmacopeia (USP)
  • European Pharmacopoeia (EP)
  • Japanese Pharmacopeia (JP).

Analytical methods exist to characterize specific products and the potential impact of material selection on a product's performance.

Thickness and mass play a role in the determination of dissolution rates. Constructions composed predominantly of low-MW, water-soluble polymers at different thicknesses will result in a range of rapid disintegration rates and mechanical strengths. High-MW polymers tend to impart good mechanical properties; however, disintegration time is increased (9).

Future applications may require films that demonstrate specific dissolution rates to release drugs in different physiological conditions (e.g., neutral–alkaline pH). Such appliations can be created by adjusting film thickness or adding excipients that control the release. Dispersed-phase filler particles can be included to add bulk to the film, increase the solids portion to facilitate coating, or alter dissolution rates. When distributed throughout the film layer, air or other gases can also change the dissolution time (10).

Material options for API liquid casting . The flexibility of the OTF delivery format provides an unlimited set of raw materials to select from when developing and delivering APIs. These materials include traditional aqueous-soluble and solvent-soluble (nonaqueous soluble) ingredients (2). API-containing liquid formulations may be in the form of a solution, emulsion, suspension, or dispersion.

  • Solutions: all ingredients, including drug substances, are fully dissolved and soluble in the bulk liquid
  • Emulsions: these are typically used for aqueous formulations to which an oil-soluble ingredient such as a flavoring has been added
  • Suspensions or dispersions: nonsoluble APIs or other excipients may be added to the bulk-liquid formulation under careful controls before casting to assure the dispersed phase remains suspended for uniformity.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
11%
Protecting the supply chain
37%
Expedited reviews of drug submissions
11%
More stakeholder involvement
11%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here